KlothovsLivagen

Klotho is a single-pass transmembrane protein primarily expressed in the kidney, parathyroid gland, and choroid plexus, with a soluble form (s-Klotho) cleaved from the membrane and circulating systemically as an endocrine factor. It exists in three forms — alpha-Klotho (the most studied, anti-ageing form), beta-Klotho (which partners with FGF21), and gamma-Klotho — each with distinct receptor partnerships and tissue effects.

At the receptor level, alpha-Klotho is the obligate co-receptor for fibroblast growth factor 23 (FGF23), enabling FGF23 to bind and activate FGFR1 receptors in the kidney to regulate phosphate excretion. This makes Klotho a central node in mineral metabolism. Beyond this canonical role, soluble Klotho exerts numerous endocrine effects: it inhibits the IGF-1/insulin signalling pathway (a conserved longevity mechanism shared with caloric restriction), enhances expression of antioxidant enzymes via FoxO transcription factor activation, suppresses Wnt signalling (reducing stem cell exhaustion), inhibits TGF-beta signalling (preventing fibrosis), and blocks NF-kB and NLRP3 inflammasome activation (reducing inflammaging).

The ageing phenotype connection is striking: mice lacking Klotho develop multi-organ ageing — atherosclerosis, osteoporosis, skin atrophy, cognitive decline — within weeks of birth, while mice with elevated Klotho expression live up to 30% longer than controls. In humans, circulating Klotho levels decline with age, and lower levels associate with increased mortality and chronic disease risk in observational studies. Recombinant alpha-Klotho is in early clinical development as a potential therapy for chronic kidney disease, cognitive decline, and broader age-related diseases. The 2026 research wave around Klotho has positioned it as one of the most promising single-protein interventions in the longevity field, though no therapeutic Klotho product is yet approved for human use.

Livagen is a short tripeptide (Lys-Glu-Asp) within the Khavinson bioregulator family — peptides hypothesised to regulate gene expression in tissue-specific ways by binding to gene promoter regions. Livagen is positioned as the liver-targeted member of this family, intended to modulate hepatocyte gene expression in ways that support liver regeneration and counteract age-related decline in hepatic function.

Proposed mechanisms include modulation of chromatin condensation states in hepatocyte and lymphocyte nuclei, upregulation of genes involved in hepatic detoxification pathways (cytochrome P450 enzymes, glutathione synthesis), and immunomodulatory effects in liver-resident immune cells. Russian research has reported livagen-induced increases in hepatocyte regeneration markers in animal models of liver injury and changes in lymphocyte chromatin organisation consistent with cellular rejuvenation.

As with all Khavinson tripeptides, the proposed action model is that livagen acts as a transient signalling molecule triggering longer-lasting changes in gene expression. Plasma exposure is brief (around 30 minutes) but downstream transcriptional effects are claimed to persist for weeks, justifying pulse-dosing protocols of 10-30 day courses repeated periodically. The evidence base for clinical efficacy is dominated by Russian gerontology research with limited independent Western replication, and clinical use outside Russia remains largely anecdotal. Livagen should not be used as a substitute for evidence-based liver disease management.